Last updated: October 04, 2026

Application No. 17/540,310

BISPECIFIC NANOBODIES

Final Rejection

Filed

Dec 02, 2021

Priority

Sep 26, 2013 — provisional 61/882,877 +2 more

Examiner

AEDER, SEAN E

Art Unit

1642

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Ablynx N.V.

OA Round

10 (Final)

This examiner grants 57% of cases after interview

— +19.9% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 1431 resolved cases, 2023–2026

Examiner Intelligence

AEDER, SEAN E View full profile →

Grants 57% of resolved cases

Career Allowance Rate

816 granted / 1431 resolved

-3.0% vs TC avg

Strong +20% interview lift

Without

With

+19.9%

Interview Lift

resolved cases with interview

Typical timeline

3y 0m

Avg Prosecution

70 currently pending

Career history

1495

Total Applications

across all art units

Statute-Specific Performance

§101

14.7%

-25.3% vs TC avg

§103

26.5%

-13.5% vs TC avg

§102

17.1%

-22.9% vs TC avg

§112

27.2%

-12.8% vs TC avg

Black line = Tech Center average estimate • Based on career data from 1431 resolved cases

Prosecution Timeline

Show 16 earlier events

Sep 11, 2025

Non-Final Rejection mailed

Dec 09, 2025

Response Filed

Jan 20, 2026

Final Rejection mailed

Apr 20, 2026

Request for Continued Examination

Apr 22, 2026

Response after Non-Final Action

May 01, 2026

Non-Final Rejection mailed

Jul 31, 2026

Response Filed

Aug 19, 2026

Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/924,982

Patent 12746272

METHOD OF TREATMENT OF CANCER OR TUMOUR

3y 8m to grant Granted Sep 29, 2026

18/297,979

Patent 12742780

METHODS FOR THE DETECTION AND TREATMENT OF OVARIAN CANCER

3y 5m to grant Granted Sep 22, 2026

18/457,729

Patent 12735485

BISPECIFIC ANTIGEN BINDING MOLECULES TARGETING OX40 AND FAP

3y 0m to grant Granted Sep 15, 2026

17/595,665

Patent 12710425

COMPOSITION FOR CANCER DIAGNOSIS

4y 9m to grant Granted Aug 18, 2026

17/968,386

Patent 12685734

N6-Methyladenosine Regulators in Uterine Fibroids

3y 9m to grant Granted Jul 21, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

11-12

Expected OA Rounds

57%

Grant Probability

77%

With Interview (+19.9%)

3y 0m (~0m remaining)

Median Time to Grant

High

PTA Risk

Based on 1431 resolved cases by this examiner. Grant probability derived from career allowance rate.